All In Biotech

Drug Trial Radar · NCT00624130

Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers

Open, Randomized, Parallel Multi-center Comparison of Cycle Control and Safety of the Oral Contraceptive Yasmin 20 in a 24-day Regimen vs. Mercilon for 7 Cycles in 440 Healthy Female Volunteers

Last checked: Nov 20, 2026Latest source record: Dec 31, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 453 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

453

Actual

Start

Mar 2004

Primary completion

Not stated

Study completion Jun 2005

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Feb 26, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare bleeding pattern of contraceptive Yasmin 20 to a marketed comparator.

Conditions

  • Contraception

Interventions

  • Yasmin 20Drug

    Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)

  • MercilonDrug

    Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cycle control and bleeding patternTime frame: 7 cycles

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Horn, Austria

  • Site not named

    Leibnitz, Styria, Austria

  • Site not named

    Mödling, Austria

  • Site not named

    Sankt Pölten, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Wörgl, Austria

  • Site not named

    Pärnu, Estonia

  • Site not named

    Talinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Helsinki, Finland

  • Site not named

    Helsinki, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Turku, Finland

  • Site not named

    Kaunas, Lithuania

  • Site not named

    Kaunas, Lithuania

  • Site not named

    Vilnius, Lithuania

  • Site not named

    Vilnius, Lithuania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.